Resistance artery mechanics and composition in angiotensin II-infused rats: Effects of aldosterone antagonism

Journal of Hypertension

Volumn 21, Issue 1, 2003, Pages 189-198

  Neves, Mario Fritsch ^a   Virdis, Agostino ^a   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Collagen; Fibrosis; Hypertension; Small arteries; Vascular remodelling

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; HYDRALAZINE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; HORMONE ACTION; HORMONE SYNTHESIS; HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; RESISTANCE BLOOD VESSEL; STRESS STRAIN RELATIONSHIP; YOUNG MODULUS;

EID: 0037251361     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200301000-00029     Document Type: Article

References (43)

1. Laurant P, Touyz RM, Schiffrin EL. Effect of pressurization on mechanical properties of mesenteric small arteries from spontaneously hypertensive rats. J Vasc Res 1997; 34:117-125.
2. Intengan HD, Park JB, Schiffrin EL. Blood pressure and small arteries in DOCA-salt-treated genetically AVP-deficient rats. Hypertension 1999; 34:907-913.
3. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 1999; 33:569-574.
4. Van Bortel LMAB, Struijker-Boudier HAJ, Safar ME. Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension 2001; 38:914-921.
5. Baumbach GL, Hajdu MA. Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. Hypertension 1993; 21:816-826.
6. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999; 100:2267-2275.
7. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52:639-672.
8. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol Heart Circ Physiol 1984; 246:H608-H614.
9. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 1985; 63:1522-1527.
10. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992; 20:67-73.
11. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996; 32:266-273.
12. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 289:24316-24320.
13. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995; 25:170-173.
14. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997; 29:45-48.
15. Duprez D, De Buyzere M, Rietzschel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2:327-334.
16. Slight SH, Joseph J, Ganjam VK, Weber KT. Extra-adrenal mineralocorticolds and cardiovascular tissues. J Mol Cell Cardiol 1999; 31: 1175-1184.
17. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension. Dual process of remodeling and growth. Hypertension 1993; 21:391-397.
18. Dickhout JG, Lee RMKW. Structural and functional analysis of small arteries from young spontaneously hypertensive rats. Hypertension 1997; 29:781-789.
19. Schiffrin EL, Thome FS, Genest J. Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats. Hypertension 1983; 5:V16-V21.
20. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33:232-237.
21. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52:11-34.
22. Luft FC. Mechanisms and cardiovascular damage in hypertension. Hypertension 2001; 37:594-598.
23. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991; 17:626-635.
24. O'Callaghan CJ, Williams B. The regulation of human vascular smooth muscle extracellular matrix protein production by α and β adrenoceptor stimulation. J Hypertens 2002; 20:287-294.
25. Schiffrin EL. Vascular smooth muscle growth and extracellular matrix deposition: is there a role for the sympathetic nervous system? J Hypertens 2002; 20:179-181.
26. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension [review]. Hypertension 2000; 36:312-318.
27. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga, Sato A, Saruta T. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991; 9:17-22.
28. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26:809-20.
29. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002; 15:164-169.
30. Brilla CG. The cardiac structure-function relationship and the reninangiotensin-aldosterone system in hypertension and heart failure. Curr Opin Cardiol 1994; 9 (Suppl I):S2-S10.
31. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension. Roles of apoptosis and fibrosis. Hypertension 2001; 38:581-587.
32. Bézie Y, Lamazière D, Laurent S, Challande P, Sa Cunha R, Bonnet J, Lacolley P. Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Artenoscter Thromb Vasc Biol 1998; 18:1027-1034.
33. Intengan HD, Schiffrin EL. Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats: role of endothelin-1. J Hypertens 1998; 16:1907-1912.
34. Intengan HD, He G, Schiffrin EL. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats. Hypertension 1998; 32:770-777.
35. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, Safar ME. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997; 10:1326-1334.
36. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19:1371-1376.
37. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17:1152-1156.
38. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286:441-449.
39. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33:261-266.
40. Schlaich MP, Klingbeil AU, Jacobi J, Delles C, Schneider MP, Schmidt BMW, Schmieder RE. Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. J Hypertens 2002; 20:117-124.
41. A receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37:1444-1449.
42. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans, J Clin Endocrinol Metabol 2002; 87:448-452.
43. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71:503-510.